FDA Grants Priority Review for Roche's Tecentriq in Stage III Colon Cancer

The U.S. Food and Drug Administration has accepted Roche's supplemental application for adjuvant Tecentriq (atezolizumab) in combination with chemotherapy for stage III colon cancer patients with specific genetic markers. The FDA's Priority Review designation indicates an expedited assessment, with a decision expected by October 9, 2026. This submission is based on a Phase III study showing the combination reduced recurrence or death risk by 50%.